Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Citigroup Maintains Buy on FormFactor, Lowers Price Target to $42

Citigroup Maintains Buy on FormFactor, Lowers Price Target to $42

Citigroup analyst Amanda Scarnati maintains FormFactor (NASDAQ:FORM) with a Buy and lowers the price target from $45 to $42.

byBenzinga Newsdesk

July 29, 2022

1 minute read

Citigroup analyst Amanda Scarnati maintains FormFactor (NASDAQ:FORM) with a Buy and lowers the price target from $45 to $42.

AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report

By Benzinga Neuro

May 27, 7:12 AM

Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers.

AZN

News

New York Hall of Science, Verizon And Snap launch Citywide Augmented Reality Experience

By Happy Mohamed

April 26, 11:25 AM

The New York Hall of Science has teamed up with Verizon and Snap to launch "Science City Explorers," a citywide augmented reality experience that allows people to learn the science in common public

SNAP

Seeing Reports Of Attack On FBI Building In Cincinnati

By Benzinga Newsdesk

August 11, 11:24 AM

https://twitter.com/mynbc15/status/1557745287283736577

SPY

These Are The Only EVs That Qualify For Federal Tax Credits From Today

By Anan Ashraf

April 18, 7:16 AM

Just over a dozen fully electric vehicles are eligible for a $7,500 tax credit in the U.S. from…

BMWYY

Citigroup Maintains Buy on FormFactor, Lowers Price Target to $42

Related Posts

AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report

New York Hall of Science, Verizon And Snap launch Citywide Augmented Reality Experience

Seeing Reports Of Attack On FBI Building In Cincinnati

These Are The Only EVs That Qualify For Federal Tax Credits From Today